Skip to main content

Table 2 Body composition, femur length, femur and whole body BMC and BMD

From: Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

Group Control (n = 12) Fenofibrate (n = 11) Pioglitazone (n = 8)
Body weight
(g)
237 ± 14.9 243 ± 9.60 240 ± 8.70
Fat mass
(g)
46.8 ± 13.7 41.2 ± 6.94 62.5 ± 8.42**/###
Lean mass
(g)
184 ± 7.73 195 ± 8.98** 171 ± 8.87**/###
Femur length
(cm)
33.9 ± 0.44 34.1 ± 0.53 33.5 ± 0.57
Femoral BMC
(g)
3.56 ± 0.30 3.78 ± 0.28 3.39 ± 0.26##
Femoral BMD
(g/cm2)
0.245 ± 0.009 0.259 ± 0.001** 0.235 ± 0.001###
Whole body BMC
(g)
7.23 ± 0.36 7.36 ± 0.26 6.87 ± 0.40*/##
Whole body BMD
(g/cm2)
0.159 ± 0.008 0.157 ± 0.005 0.143 ± 0.002***/###
  1. BMC = bone mineral content, BMD = bone mineral density. Data is presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 significantly different compared to control, ##P < 0.01, ###P < 0.001 significantly different compared to fenofibrate-treated group.